🎯 Extending the Half-Life of mAbs: Why It Matters in IBD In Crohn’s disease and ulcerative colitis, therapeutic monoclonal antibodies often require frequent dosing—which can burden patients and strain healthcare systems. 🧬 Enter Fc engineering: By tweaking the Fc region of antibodies, we can achieve: ✅ Longer half-life ✅ Reduced dosing frequency ✅ Better mucosal drug retention ✅ Lower immunogenicity risk This fun cartoon breaks down 6 key Fc engineering strategies—including YTE, LS, LALA (Remember Risankizumab! ) , and catch-and-release—with direct applications for managing IBD. Imagine future mAbs needing only 1 injection every 4-6 months or even longer, with less immune activation and greater mucosal healing. We're not far off!